Fermenta Biotech Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: May 31, 2025, 7:47 pm

Market Cap	918 Cr.
Current Price	312
High / Low	449/145
Stock P/E	12.0
Book Value	123
Dividend Yield	0.40 %
ROCE	21.7 %
ROE	23.4 %
Face Value	5.00
PEG Ratio	-2.48

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Fermenta Biotech Ltd

Competitors of Fermenta Biotech Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	134 Cr.	95.0	247/84.3	26.0	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.27 Cr.	2.76	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	39.9 Cr.	53.8	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	41.1 Cr.	28.0	29.1/13.1	40.3	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,354.98 Cr	1,129.60		88.53	194.54	0.32%	16.70%	15.22%	6.19

All Competitor Stocks of Fermenta Biotech Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	96	92	98	55	105	82	57	99	97	78	95	156	140
Expenses	78	87	95	65	86	72	71	74	92	77	76	103	103
Operating Profit	18	5	3	-10	19	11	-14	25	5	1	19	53	37
OPM %	18%	5%	3%	-18%	18%	13%	-24%	25%	6%	1%	20%	34%	26%
Other Income	3	4	3	-19	-8	2	-6	3	5	3	3	2	4
Interest	4	4	5	5	6	5	4	5	3	3	4	4	3
Depreciation	6	7	9	6	6	6	6	6	6	6	6	6	6
Profit before tax	10	-2	-8	-41	-1	2	-29	16	1	-6	12	45	32
Tax %	21%	8%	6%	-8%	373%	0%	0%	38%	885%	0%	6%	16%	-4%
Net Profit	8	-3	-8	-38	-5	2	-29	10	-7	-6	11	38	33
EPS in Rs	2.61	-0.88	-2.75	-12.70	-1.40	0.62	-9.70	3.35	-2.36	-1.98	3.87	12.54	11.68

Last Updated: May 31, 2025, 6:04 am

Below is a detailed analysis of the quarterly data for Fermenta Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 140.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Dec 2024) to 140.00 Cr., marking a decrease of 16.00 Cr..
For Expenses, as of Mar 2025, the value is 103.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 103.00 Cr..
For Operating Profit, as of Mar 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 53.00 Cr. (Dec 2024) to 37.00 Cr., marking a decrease of 16.00 Cr..
For OPM %, as of Mar 2025, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 34.00% (Dec 2024) to 26.00%, marking a decrease of 8.00%.
For Other Income, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Dec 2024) to 4.00 Cr., marking an increase of 2.00 Cr..
For Interest, as of Mar 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Dec 2024) to 3.00 Cr., marking a decrease of 1.00 Cr..
For Depreciation, as of Mar 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 6.00 Cr..
For Profit before tax, as of Mar 2025, the value is 32.00 Cr.. The value appears to be declining and may need further review. It has decreased from 45.00 Cr. (Dec 2024) to 32.00 Cr., marking a decrease of 13.00 Cr..
For Tax %, as of Mar 2025, the value is -4.00%. The value appears to be improving (decreasing) as expected. It has decreased from 16.00% (Dec 2024) to -4.00%, marking a decrease of 20.00%.
For Net Profit, as of Mar 2025, the value is 33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 38.00 Cr. (Dec 2024) to 33.00 Cr., marking a decrease of 5.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 11.68. The value appears to be declining and may need further review. It has decreased from 12.54 (Dec 2024) to 11.68, marking a decrease of 0.86.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 4:03 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	117	139	142	155	164	302	403	292	376	397	349	335	427
Expenses	94	113	126	134	152	209	248	225	293	335	330	307	349
Operating Profit	23	26	16	21	12	93	156	66	83	62	18	28	78
OPM %	20%	19%	11%	13%	7%	31%	39%	23%	22%	16%	5%	8%	18%
Other Income	2	3	0	1	3	9	6	12	8	8	-20	4	13
Interest	5	5	4	6	10	14	21	20	19	18	21	17	15
Depreciation	9	10	9	8	10	12	12	15	20	26	28	25	25
Profit before tax	10	14	3	7	-6	76	129	43	52	27	-51	-10	52
Tax %	36%	24%	67%	61%	49%	28%	8%	-37%	18%	44%	4%	143%
Net Profit	4	10	1	2	-9	46	117	60	43	15	-53	-24	36
EPS in Rs	1.51	2.86	0.17	-0.41	-4.14	12.21	42.71	20.23	15.46	5.25	-17.36	-7.84	12.07
Dividend Payout %	124%	29%	249%	-51%	-5%	2%	1%	24%	16%	23%	-7%	-16%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	150.00%	-90.00%	100.00%	-550.00%	611.11%	154.35%	-48.72%	-28.33%	-65.12%	-453.33%	54.72%
Change in YoY Net Profit Growth (%)	0.00%	-240.00%	190.00%	-650.00%	1161.11%	-456.76%	-203.07%	20.38%	-36.78%	-388.22%	508.05%

Fermenta Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	13%
5 Years:	10%
3 Years:	6%
TTM:	40%

Compounded Profit Growth
10 Years:	66%
5 Years:	6%
3 Years:	72%
TTM:	552%

Stock Price CAGR
10 Years:	21%
5 Years:	5%
3 Years:	13%
1 Year:	101%

Return on Equity
10 Years:	12%
5 Years:	6%
3 Years:	4%
Last Year:	23%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 1:43 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	2	2	2	2	2	2	5	14	14	14	14	14	14
Reserves	125	130	129	128	142	122	246	295	346	358	301	274	276
Borrowings	43	65	71	89	87	173	209	224	232	239	220	139	125
Other Liabilities	55	61	60	70	75	87	92	80	94	96	102	120	125
Total Liabilities	226	259	262	288	307	385	551	614	687	707	637	548	539
Fixed Assets	94	87	85	168	172	177	178	200	263	299	267	269	258
CWIP	15	36	65	6	5	4	22	71	57	35	45	2	6
Investments	11	17	18	15	18	10	8	0	0	0	3	0	0
Other Assets	105	118	94	99	112	193	344	342	367	373	321	277	274
Total Assets	226	259	262	288	307	385	551	614	687	707	637	548	539

Below is a detailed analysis of the balance sheet data for Fermenta Biotech Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.00 Cr..
For Reserves, as of Sep 2024, the value is 276.00 Cr.. The value appears strong and on an upward trend. It has increased from 274.00 Cr. (Mar 2024) to 276.00 Cr., marking an increase of 2.00 Cr..
For Borrowings, as of Sep 2024, the value is 125.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 139.00 Cr. (Mar 2024) to 125.00 Cr., marking a decrease of 14.00 Cr..
For Other Liabilities, as of Sep 2024, the value is 125.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 120.00 Cr. (Mar 2024) to 125.00 Cr., marking an increase of 5.00 Cr..
For Total Liabilities, as of Sep 2024, the value is 539.00 Cr.. The value appears to be improving (decreasing). It has decreased from 548.00 Cr. (Mar 2024) to 539.00 Cr., marking a decrease of 9.00 Cr..
For Fixed Assets, as of Sep 2024, the value is 258.00 Cr.. The value appears to be declining and may need further review. It has decreased from 269.00 Cr. (Mar 2024) to 258.00 Cr., marking a decrease of 11.00 Cr..
For CWIP, as of Sep 2024, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 6.00 Cr., marking an increase of 4.00 Cr..
For Investments, as of Sep 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Other Assets, as of Sep 2024, the value is 274.00 Cr.. The value appears to be declining and may need further review. It has decreased from 277.00 Cr. (Mar 2024) to 274.00 Cr., marking a decrease of 3.00 Cr..
For Total Assets, as of Sep 2024, the value is 539.00 Cr.. The value appears to be declining and may need further review. It has decreased from 548.00 Cr. (Mar 2024) to 539.00 Cr., marking a decrease of 9.00 Cr..

Notably, the Reserves (276.00 Cr.) exceed the Borrowings (125.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	14	15	4	2	59	90	34	63	43	116	105
Cash from Investing Activity +	-25	-18	-13	7	-101	-97	-44	-41	-26	-55	-16
Cash from Financing Activity +	13	1	10	-12	89	12	-47	-1	-22	-41	-91
Net Cash Flow	2	-2	1	-4	47	6	-57	21	-4	19	-1

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-20.00	-39.00	-55.00	-68.00	-75.00	-80.00	-53.00	-158.00	-149.00	-177.00	-202.00	-111.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	79	106	91	101	99	83	59	87	66	80	44	76
Inventory Days	225	149	125	160	208	234	347	594	441	380	309	245
Days Payable	134	120	95	113	147	183	169	260	169	154	109	182
Cash Conversion Cycle	171	136	122	148	160	134	237	421	338	306	244	139
Working Capital Days	72	73	4	20	115	90	97	202	171	180	123	108
ROCE %	8%	9%	3%	6%	2%	31%	41%	12%	13%	7%	-0%	3%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	59.58%	59.58%	59.58%	59.58%	59.58%	59.58%	62.06%	62.06%	62.06%	62.06%	62.06%	62.06%
FIIs	0.01%	0.01%	0.01%	0.01%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.05%
DIIs	0.05%	0.05%	0.05%	0.05%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	38.37%	38.37%	38.37%	38.38%	38.45%	38.46%	36.00%	36.04%	36.05%	36.05%	36.11%	36.41%
Others	1.98%	1.98%	1.98%	1.98%	1.95%	1.95%	1.92%	1.89%	1.89%	1.89%	1.82%	1.47%
No. of Shareholders	18,578	17,518	17,472	17,971	17,610	16,897	16,148	15,721	15,150	15,178	14,589	13,221

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	5.00	5.00	5.00	5.00	5.00
Basic EPS (Rs.)	-7.99	-17.85	5.33	15.77	20.63
Diluted EPS (Rs.)	-7.99	-17.85	5.33	15.69	20.63
Cash EPS (Rs.)	0.24	-8.77	14.08	21.78	25.83
Book Value[Excl.RevalReserv]/Share (Rs.)	98.76	108.08	128.76	124.90	107.27
Book Value[Incl.RevalReserv]/Share (Rs.)	98.76	108.08	128.76	124.90	107.27
Revenue From Operations / Share (Rs.)	116.25	121.27	138.15	130.79	101.55
PBDIT / Share (Rs.)	13.62	8.88	24.12	31.17	26.89
PBIT / Share (Rs.)	5.06	-0.90	15.26	24.13	21.69
PBT / Share (Rs.)	-3.42	-17.98	9.34	17.90	15.05
Net Profit / Share (Rs.)	-8.31	-18.56	5.22	14.74	20.63
NP After MI And SOA / Share (Rs.)	-7.99	-17.85	5.35	15.77	20.63
PBDIT Margin (%)	11.71	7.32	17.46	23.83	26.47
PBIT Margin (%)	4.34	-0.74	11.04	18.44	21.35
PBT Margin (%)	-2.94	-14.82	6.76	13.68	14.82
Net Profit Margin (%)	-7.15	-15.30	3.77	11.27	20.31
NP After MI And SOA Margin (%)	-6.86	-14.71	3.87	12.06	20.31
Return on Networth / Equity (%)	-7.98	-16.36	4.15	12.62	19.23
Return on Capital Employeed (%)	3.89	-0.61	8.81	14.56	14.92
Return On Assets (%)	-4.20	-8.09	2.18	6.62	9.69
Long Term Debt / Equity (X)	0.14	0.26	0.30	0.30	0.32
Total Debt / Equity (X)	0.45	0.68	0.63	0.57	0.66
Asset Turnover Ratio (%)	0.56	0.52	0.55	0.57	0.51
Current Ratio (X)	1.40	1.21	1.52	1.48	1.46
Quick Ratio (X)	0.89	0.58	0.74	0.70	0.79
Inventory Turnover Ratio (X)	0.70	0.77	0.91	1.06	1.02
Dividend Payout Ratio (NP) (%)	-15.65	-7.00	46.68	0.00	12.09
Dividend Payout Ratio (CP) (%)	217.49	-15.50	17.58	0.00	9.65
Earning Retention Ratio (%)	115.65	107.00	53.32	0.00	87.91
Cash Earning Retention Ratio (%)	-117.49	115.50	82.42	0.00	90.35
Interest Coverage Ratio (X)	2.31	1.23	4.07	5.00	4.05
Interest Coverage Ratio (Post Tax) (X)	0.02	-0.20	1.88	3.37	4.11
Enterprise Value (Cr.)	505.89	464.45	795.24	883.96	786.75
EV / Net Operating Revenue (X)	1.51	1.33	2.00	2.34	2.69
EV / EBITDA (X)	12.87	18.12	11.43	9.83	10.14
MarketCap / Net Operating Revenue (X)	1.30	0.88	1.49	1.91	2.09
Retention Ratios (%)	115.65	107.00	53.31	0.00	87.90
Price / BV (X)	1.51	0.98	1.59	2.00	1.98
Price / Net Operating Revenue (X)	1.30	0.88	1.49	1.91	2.10
EarningsYield	-0.05	-0.16	0.02	0.06	0.09

After reviewing the key financial ratios for Fermenta Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
For Basic EPS (Rs.), as of Mar 24, the value is -7.99. This value is below the healthy minimum of 5. It has increased from -17.85 (Mar 23) to -7.99, marking an increase of 9.86.
For Diluted EPS (Rs.), as of Mar 24, the value is -7.99. This value is below the healthy minimum of 5. It has increased from -17.85 (Mar 23) to -7.99, marking an increase of 9.86.
For Cash EPS (Rs.), as of Mar 24, the value is 0.24. This value is below the healthy minimum of 3. It has increased from -8.77 (Mar 23) to 0.24, marking an increase of 9.01.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 98.76. It has decreased from 108.08 (Mar 23) to 98.76, marking a decrease of 9.32.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 98.76. It has decreased from 108.08 (Mar 23) to 98.76, marking a decrease of 9.32.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 116.25. It has decreased from 121.27 (Mar 23) to 116.25, marking a decrease of 5.02.
For PBDIT / Share (Rs.), as of Mar 24, the value is 13.62. This value is within the healthy range. It has increased from 8.88 (Mar 23) to 13.62, marking an increase of 4.74.
For PBIT / Share (Rs.), as of Mar 24, the value is 5.06. This value is within the healthy range. It has increased from -0.90 (Mar 23) to 5.06, marking an increase of 5.96.
For PBT / Share (Rs.), as of Mar 24, the value is -3.42. This value is below the healthy minimum of 0. It has increased from -17.98 (Mar 23) to -3.42, marking an increase of 14.56.
For Net Profit / Share (Rs.), as of Mar 24, the value is -8.31. This value is below the healthy minimum of 2. It has increased from -18.56 (Mar 23) to -8.31, marking an increase of 10.25.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -7.99. This value is below the healthy minimum of 2. It has increased from -17.85 (Mar 23) to -7.99, marking an increase of 9.86.
For PBDIT Margin (%), as of Mar 24, the value is 11.71. This value is within the healthy range. It has increased from 7.32 (Mar 23) to 11.71, marking an increase of 4.39.
For PBIT Margin (%), as of Mar 24, the value is 4.34. This value is below the healthy minimum of 10. It has increased from -0.74 (Mar 23) to 4.34, marking an increase of 5.08.
For PBT Margin (%), as of Mar 24, the value is -2.94. This value is below the healthy minimum of 10. It has increased from -14.82 (Mar 23) to -2.94, marking an increase of 11.88.
For Net Profit Margin (%), as of Mar 24, the value is -7.15. This value is below the healthy minimum of 5. It has increased from -15.30 (Mar 23) to -7.15, marking an increase of 8.15.
For NP After MI And SOA Margin (%), as of Mar 24, the value is -6.86. This value is below the healthy minimum of 8. It has increased from -14.71 (Mar 23) to -6.86, marking an increase of 7.85.
For Return on Networth / Equity (%), as of Mar 24, the value is -7.98. This value is below the healthy minimum of 15. It has increased from -16.36 (Mar 23) to -7.98, marking an increase of 8.38.
For Return on Capital Employeed (%), as of Mar 24, the value is 3.89. This value is below the healthy minimum of 10. It has increased from -0.61 (Mar 23) to 3.89, marking an increase of 4.50.
For Return On Assets (%), as of Mar 24, the value is -4.20. This value is below the healthy minimum of 5. It has increased from -8.09 (Mar 23) to -4.20, marking an increase of 3.89.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.14. This value is below the healthy minimum of 0.2. It has decreased from 0.26 (Mar 23) to 0.14, marking a decrease of 0.12.
For Total Debt / Equity (X), as of Mar 24, the value is 0.45. This value is within the healthy range. It has decreased from 0.68 (Mar 23) to 0.45, marking a decrease of 0.23.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.56. It has increased from 0.52 (Mar 23) to 0.56, marking an increase of 0.04.
For Current Ratio (X), as of Mar 24, the value is 1.40. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 23) to 1.40, marking an increase of 0.19.
For Quick Ratio (X), as of Mar 24, the value is 0.89. This value is below the healthy minimum of 1. It has increased from 0.58 (Mar 23) to 0.89, marking an increase of 0.31.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.70. This value is below the healthy minimum of 4. It has decreased from 0.77 (Mar 23) to 0.70, marking a decrease of 0.07.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is -15.65. This value is below the healthy minimum of 20. It has decreased from -7.00 (Mar 23) to -15.65, marking a decrease of 8.65.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 217.49. This value exceeds the healthy maximum of 50. It has increased from -15.50 (Mar 23) to 217.49, marking an increase of 232.99.
For Earning Retention Ratio (%), as of Mar 24, the value is 115.65. This value exceeds the healthy maximum of 70. It has increased from 107.00 (Mar 23) to 115.65, marking an increase of 8.65.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is -117.49. This value is below the healthy minimum of 40. It has decreased from 115.50 (Mar 23) to -117.49, marking a decrease of 232.99.
For Interest Coverage Ratio (X), as of Mar 24, the value is 2.31. This value is below the healthy minimum of 3. It has increased from 1.23 (Mar 23) to 2.31, marking an increase of 1.08.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.02. This value is below the healthy minimum of 3. It has increased from -0.20 (Mar 23) to 0.02, marking an increase of 0.22.
For Enterprise Value (Cr.), as of Mar 24, the value is 505.89. It has increased from 464.45 (Mar 23) to 505.89, marking an increase of 41.44.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.51. This value is within the healthy range. It has increased from 1.33 (Mar 23) to 1.51, marking an increase of 0.18.
For EV / EBITDA (X), as of Mar 24, the value is 12.87. This value is within the healthy range. It has decreased from 18.12 (Mar 23) to 12.87, marking a decrease of 5.25.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.30. This value is within the healthy range. It has increased from 0.88 (Mar 23) to 1.30, marking an increase of 0.42.
For Retention Ratios (%), as of Mar 24, the value is 115.65. This value exceeds the healthy maximum of 70. It has increased from 107.00 (Mar 23) to 115.65, marking an increase of 8.65.
For Price / BV (X), as of Mar 24, the value is 1.51. This value is within the healthy range. It has increased from 0.98 (Mar 23) to 1.51, marking an increase of 0.53.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.30. This value is within the healthy range. It has increased from 0.88 (Mar 23) to 1.30, marking an increase of 0.42.
For EarningsYield, as of Mar 24, the value is -0.05. This value is below the healthy minimum of 5. It has increased from -0.16 (Mar 23) to -0.05, marking an increase of 0.11.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Fermenta Biotech Ltd as of June 1, 2025 is: 277.41

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 1, 2025, Fermenta Biotech Ltd is Overvalued by 11.09% compared to the current share price 312.00

Intrinsic Value of Fermenta Biotech Ltd as of June 1, 2025 is: 264.01

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 1, 2025, Fermenta Biotech Ltd is Overvalued by 15.38% compared to the current share price 312.00

Last 5 Year EPS CAGR: -4.83%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (220.92 cr) compared to borrowings (147.38 cr), indicating strong financial stability. The company has shown consistent growth in sales (276.77 cr) and profit (26.62 cr) over the years.	The stock has a low average ROCE of 11.25%, which may not be favorable. The stock has a high average Working Capital Days of 104.58, which may not be favorable. The stock has a high average Cash Conversion Cycle of 213.00, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fermenta Biotech Ltd:
1. Net Profit Margin: -7.15%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 3.89% (Industry Average ROCE: 16.7%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -7.98% (Industry Average ROE: 15.22%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 0.02
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.89
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 12 (Industry average Stock P/E: 88.53)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.45
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Fermenta Biotech Ltd. is a Public Limited Listed company incorporated on 01/05/1951 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1951PLC008485 and registration number is 008485. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 307.09 Cr. and Equity Capital is Rs. 14.44 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	A-1501, Thane One, Thane Maharashtra 400610	info@fermentabiotech.com https://fermentabiotech.com

Management
Name	Position Held
Mr. Pradeep M Chandan	Chairman & Ind.Dire (Non-Exe)
Mr. Krishna Datla	Exe.Vice Chairman & Whole Time Director
Mr. Prashant Nagre	Managing Director
Mr. Satish Varma	Executive Director
Ms. Anupama Datla Desai	Executive Director
Ms. Rajeshwari Datla	Non Executive Director
Mr. Pramod Kasat	Ind. Non-Executive Director
Ms. Rajashri Ojha	Ind. Non-Executive Director

FAQ

What is the intrinsic value of Fermenta Biotech Ltd?

Fermenta Biotech Ltd's intrinsic value (as of 31 May 2025) is ₹277.41 — 11.09% lower the current market price of 312.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 918 Cr. market cap, FY2025-2026 high/low of ₹449/145, reserves of 276 Cr, and liabilities of 539 Cr.

What is the Market Cap of Fermenta Biotech Ltd?

The Market Cap of Fermenta Biotech Ltd is 918 Cr..

What is the current Stock Price of Fermenta Biotech Ltd as on 31 May 2025?

The current stock price of Fermenta Biotech Ltd as on 31 May 2025 is 312.

What is the High / Low of Fermenta Biotech Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Fermenta Biotech Ltd stocks is ₹449/145.

What is the Stock P/E of Fermenta Biotech Ltd?

The Stock P/E of Fermenta Biotech Ltd is 12.0.

What is the Book Value of Fermenta Biotech Ltd?

The Book Value of Fermenta Biotech Ltd is 123.

What is the Dividend Yield of Fermenta Biotech Ltd?

The Dividend Yield of Fermenta Biotech Ltd is 0.40 %.

What is the ROCE of Fermenta Biotech Ltd?

The ROCE of Fermenta Biotech Ltd is 21.7 %.

What is the ROE of Fermenta Biotech Ltd?

The ROE of Fermenta Biotech Ltd is 23.4 %.

What is the Face Value of Fermenta Biotech Ltd?

The Face Value of Fermenta Biotech Ltd is 5.00.